Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy
To the Editor: Effective systemic therapies have improved survival in advanced melanoma, resulting in a higher lifetime risk for brain metastases. 1 Male sex, truncal or head and neck location, and thick or ulcerated primary lesions are well-accepted risk factors. 2 Histologic subtype, however, has not been extensively studied. We report 1 of the largest series of melanoma brain metastases (MBMs) to better define clinicopathologic risk factors and guide management and surveillance decisions.
An institutional melanoma database review identified 3756 patients in whom metastatic melanoma had been diagnosed between diagnosed 1971 and 2013. Patients were divided into 2 groups on the basis of whether they developed MBMs. Primary end points were development of MBMs and 2-year MBM-free survival (MBMFS). The secondary end point was overall survival (OS).
Of the 2132 patients included in the final analysis, 397 (18.6%) developed brain metastases. Univariable analysis identified sex, primary location, ulceration, and histologic subtype as predictors of 2-year MBMFS in patients who developed stage IV disease (Fig 1) . Multivariable analyses demonstrated that axial location (P \ .01), presence of ulceration (P ¼ .04), and desmoplastic (P ¼ .02) and nodular (P ¼ .03) histologic variants were associated with a higher risk for development of MBMs. The presence (Table I ). Ipilimumab had no significant effect on the incidence or timing of MBMs. An inferior 2-year OS was seen with male sex (hazard ratio [HR], 1.15; P ¼ .02), older age (HR, 1.01; P ¼ .01), axial location (HR, 1.14; P ¼ .03), and ulceration (HR, 1.19; P \ .01). Patients treated with ipilimumab (HR, 0.16; P \ .01) demonstrated improved 2-year OS. Of the 25 patients in whom desmoplastic melanoma was diagnosed, 9 (36%) were found to have MBMs, all within the first year after the diagnosis of other systemic disease. The primary lesion was more than 4.0 mm deep in 7 of 9 patients (78%) and located in the head and neck region in 6 of 9 (67%).
Proposed mechanisms include travel along the external surface of vessels (angiotropism) and nerves (neurotropism). In a case series of 20 patients with MBM, 14 showed angiotropism in the primary lesion. The tumors with angiotropism had an average time to MBM of 33 months compared with 57 months in the melanomas without angiotropism, although the difference was not statistically significant. 3 The largest series of desmoplastic melanomas described 4 patients with neurotropism involving named nerves of the head and neck. 4 Survival after diagnosis of stage IV disease has been shown to be significantly lower in patients with isolated MBM than in those with multiple metastatic sites. 5 Our results differed, perhaps as a result of newer treatment options (ie, stereotactic radiosurgery). Although many of these patients are traditionally excluded from clinical trials, our findings suggest they should be given equal consideration.
This study identifies the desmoplastic subtype as a strong predictor of MBM development and decreased 2-year MBMFS. In patients with the desmoplastic subtype, particularly thick lesions involving the head and neck, serial screening for central nervous system metastases with brain magnetic resonance imaging should be considered during the first year after diagnosis of stage IV disease. Table I . 1 Current guidelines recommend patch testing between 6 weeks and 6 months after resolution of NI-CADR and at least 1 month after discontinuation of oral steroids. Patch testing results for NI-CADR are reproducible in 89% of patients after a mean interval of 6.0 years. 2 European guidelines exist for testing of commercially available medications at 30% and 20% concentrations. 3 Exceptions to the guidelines exist. Location of patch testing is generally performed on the upper back, except for fixed drug eruptions, in which patch testing must be performed on previously affected skin. Results of patch tests are read according to the International Contact Dermatitis Research Group guidelines. 4 Most articles included in this review evaluated individual medications with high imputability; however, patch testing can be useful even when multiple drugs are suspected. 
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